Glaxo drops version of resveratrol "red wine" drug

* Ends development of SRT501 after disappointing results

* Continuing work on other promising compounds

* Glaxo acquired drug after buying Sirtris in 2008

LONDON, Dec 1 (BestGrowthStock) – GlaxoSmithKline (GSK.L: ) has
discontinued work on one version of a drug that mimics a
health-boosting compound found in red wine, following
disappointing clinical trial results.

Glaxo acquired the experimental medicine, known as SRT501,
when it bought biotech company Sirtris Pharmaceuticals for $720
million in 2008.

But a mid-stage Phase II study of SRT501 in patients with
multiple myeloma was suspended last May after some patients with
the disease, which is a type of blood cancer, developed kidney
problems.

A spokeswoman said on Wednesday the drugmaker had now
decided to stop work on the SRT501 development programme, since
the drug appeared to have limited efficacy in myeloma and might
exacerbate kidney complications common in this patient group.

“Going forward, we’ve decided to focus our efforts on more
selective SIRT1 activator compounds that have no chemical
relationship to SRT501,” she said.

SRT501 is a proprietary formulation of resveratrol, a
substance found in grapes and in red wine. Resveratrol is
believed to provide a number of health benefits, including
preventing heart disease and potentially slowing aging
processes.

Glaxo has been testing SRT501 and other resveratrol
compounds in a number of diseases, including cancer and
diabetes.
(Reporting by Ben Hirschler; Editing by Will Waterman)

Glaxo drops version of resveratrol "red wine" drug